NDA 022503 · Primus Pharms
Metaxalone
Metaxalone · Oral · Muscle Relaxant
Last checked: Nov 19, 2026Latest source record: May 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jun 1, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
0 Phase 3, 2 recruiting
FAERS reports
3,351
2,080 serious, 605 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 3, 2026.
Metaxalone Tablets, 640 mg, are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in adults and pediatric patients 13 years of age and older. Metaxalone Tablets, 640 mg, is a muscle relaxant, indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in adult and pediatric patients 13 years of age and older. ( 1 )
Mechanism: The mechanism of action of metaxalone as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions has not been established, but may be due to general CNS depression. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 1, 2015 Original approval · Type 3 - New Dosage Form ReviewLabelSummary Review
1 products under this application
- METAXALONE · METAXALONE 640MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Metaxalone" as an intervention, any sponsor and status, largest first.
- Pain Control After Lumbar Spine FusionPivotal-lookingStatus unknown
Rothman Institute OrthopaedicsAcademic, hospital or other
NCT06484192 · 428 participants (planned) · Start Jun 28, 2024 · Primary completion Jun 30, 2025
Drug: Naproxen 500 Mg; Ketorolac and 2 more · For: Spine Fusion; NSAID (Non-Steroidal Anti-Inflammatory Drug); Postoperative Pain
Sites: Philadelphia, Pennsylvania
- Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back PainPivotal-lookingCompleted
Montefiore Medical CenterAcademic, hospital or other
NCT03068897 · 320 participants · Start May 3, 2017 · Primary completion Jul 11, 2018
Drug: Metaxalone; Tizanidine and 2 more · For: Low Back Pain
Sites: The Bronx, New York
- The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee ArthroplastyPivotal-lookingCompleted
Rothman Institute OrthopaedicsAcademic, hospital or other
NCT04003350 · 216 participants · Start Dec 21, 2017 · Primary completion Nov 26, 2018
Drug: Oxycodone; Tramadol and 5 more · For: Osteo Arthritis Knee
Sites: Philadelphia, Pennsylvania
Primus PharmaceuticalsIndustry
NCT06157177 · 50 participants (planned) · Start Nov 15, 2023 · Primary completion Nov 15, 2026
Drug: Metaxalone 640 mg Oral Tablet · For: Sciatica Acute; Lumbar Spinal Stenosis
Sites: Auburn, Alabama; Valley Village, California; Aventura, Florida · 24 sites in all
Primus PharmaceuticalsIndustry
NCT06382662 · 20 participants · Start Apr 29, 2024 · Primary completion Dec 30, 2024
Drug: metaxalone m640 mg; tizanidine 8mg · For: Cognitive Impairment
Sites: Peoria, Arizona
- Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mgCompleted
Primus PharmaceuticalsIndustry
NCT06348303 · 20 participants · Start May 16, 2024 · Primary completion Sep 5, 2024
Drug: Metaxalone m640 mg oral tablet; Metaxalone 800 mg oral tablet · For: Healthy Participants
Sites: Columbus, Ohio
Primus PharmaceuticalsIndustry
NCT07801066 · 20 participants (planned) · Start Oct 15, 2026 · Primary completion Jan 15, 2027
Drug: Metaxalone 640 mg; Metaxalone 800 MG · For: Healthy Participants
Sites: Columbus, Ohio
- Effect of Metaxalone 640 mg (M640) on Driving, Cognition, and EEG Dynamics Compared to Tizanidine 8 mg in AdultsNot yet recruiting
Primus PharmaceuticalsIndustry
NCT07932613 · 20 participants (planned) · Start Dec 15, 2026 · Primary completion Jul 15, 2027
Drug: Metaxalone Pill; tizanidine 8 mg · For: Healthy Participant
Sites: Scottsdale, Arizona
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- completed suicide261
- drug ineffective208
- pain201
- nausea199
- fatigue198
- headache172
- toxicity to various agents164
- fall159
- diarrhoea135
- dizziness123
- dyspnoea122
- death117
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 46 |
| 2006 | 23 |
| 2007 | 28 |
| 2008 | 71 |
| 2009 | 23 |
| 2010 | 48 |
| 2011 | 75 |
| 2012 | 105 |
| 2013 | 172 |
| 2014 | 159 |
| 2015 | 283 |
| 2016 | 322 |
| 2017 | 240 |
| 2018 | 270 |
| 2019 | 366 |
| 2020 | 342 |
| 2021 | 179 |
| 2022 | 153 |
| 2023 | 96 |
| 2024 | 107 |
| 2025 | 135 |
| 2026 | 79 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Metaxalone (Metaxalone)
2024 spending
$8.5M
Beneficiaries
27,984
71,567 claims
Per beneficiary
$304
$1.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $13,465,766 |
| 2021 | $13,465,209 |
| 2022 | $11,496,332 |
| 2023 | $9,744,433 |
| 2024 | $8,495,416 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M · J Pain Symptom Manage 2004 · Comparative Study, Evaluation Study
- A Randomized, Placebo-Controlled Trial of Ibuprofen Plus Metaxalone, Tizanidine, or Baclofen for Acute Low Back Pain.
Friedman BW, Irizarry E, Solorzano C, et al. · Ann Emerg Med 2019 · Multicenter Study, Randomized Controlled Trial
- Muscle relaxants for pain management in rheumatoid arthritis.
Richards BL, Whittle SL, Buchbinder R · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Double-blind study of metaxalone; use as skeletal-muscle relaxant.
Diamond S · JAMA 1966 · Clinical Trial, Randomized Controlled Trial
- A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy.
Pfeifer MA, Ross DR, Schrage JP, et al. · Diabetes Care 1993 · Clinical Trial, Comparative Study
- A study of metaxalone (Skelaxin) vs. placebo in acute musculoskeletal disorders: a cooperative study.
Dent RW, Ervin DK · Curr Ther Res Clin Exp 1975 · Clinical Trial, Comparative Study
Sponsor: Primus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.